For the Inventor, By the Inventor

Enter assignee name

Shionogi & Co., Ltd.

USPTO Granted Patents = 15

EPO Patents = 5

Forward Citations = 0

Loading Chart...

Loading Chart...

81 inventors (with patents filed for the assignee):

Kenji Nakahara (3 out of 16 patents)

Yuto Unoh (2 out of 5 patents)

Shota Uehara (2 out of 3 patents)

4. Yutaka Tomida (2 out of 2 patents)

5. Takashi Kawasuji (1 out of 17 patents)

6. Yoshiyuki Taoda (1 out of 32 patents)

7. Kouhei Nodu (1 out of 6 patents)

8. Keiichiro Hirai (1 out of 3 patents)

9. Kouki Fuchino (1 out of 8 patents)

10. Eiichi Kojima (1 out of 11 patents)

11. Shuji Yonezawa (1 out of 7 patents)

12. Shigeru Ando (1 out of 4 patents)

13. Kana Kurahashi (1 out of 4 patents)

14. Toshiyuki Akiyama (1 out of 14 patents)

15. Tomokazu Yoshinaga (1 out of 10 patents)

15 patents: Sort by Forward Citations

1. 12751955 - FORMULATION FOR ORAL ADMINISTRATION, COMPRISING TRIAZINE DERIVATIVE (2026-10-06),

2. 12721844 - Chronic kidney disease treatment or prevention method (2026-09-01),

3. 12699104 - Heart failure marker (2026-08-04),

4. 12678089 - Signal processing apparatus and signal processing method (2026-07-14),

5. 12637443 - Cyclic amine derivatives having serotonin receptor binding activity (2026-05-26),

6. 12616389 - Estimation system, estimation method, program, estimation model, brain activity training apparatus, brain activity training method, and brain activity training program (2026-05-05),

7. 12612415 - Stereoselective process for preparing substituted polycyclic pyridone (2026-04-28),

8. 12584132 - NUCLEIC ACID DRUG TARGETING MURF1 (2026-03-24),

9. 12577241 - Polycyclic pyridopyrazine derivative (2026-03-17),

10. 12570627 - Pharmaceutical composition in which production of impurities is suppressed (2026-03-10),

11. 12564595 - Prophylactic and therapeutic pharmaceutical agent for HIV infectious diseases characterized by comprising combination of integrase inhibitor and anti-HIV agent (2026-03-03),

12. 12559474 - TRIAZINE DERIVATIVES HAVING VIRUS REPLICATION INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME (2026-02-24),

13. 12545687 - URACIL DERIVATIVES HAVING VIRUS REPLICATION INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME (2026-02-10),

14. 12528790 - Amide derivative having antiviral activity (2026-01-20),

15. 12527775 - Heteroaromatic derivatives having serotonin receptor binding activity (2026-01-20),

Company Overview

Shionogi & Co., Ltd. is a prominent pharmaceutical company based in Osaka, Japan, specializing in the research, development, and manufacturing of innovative medicines. The company focuses on therapeutic areas such as infectious diseases, pain management, and central nervous system disorders, leveraging advanced technologies to create effective treatments. With a commitment to improving patient outcomes, Shionogi engages in global collaborations to enhance its research capabilities and expand its therapeutic portfolio.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

15 Patents

#370 in Osaka

#3,443 in Japan

#39,921 in the World

Shionogi & Co., Ltd.

Forward Citations = 0

81 inventors:

Kenji Nakahara (3 out of 16 patents)

Yuto Unoh (2 out of 5 patents)

Shota Uehara (2 out of 3 patents)

4. Yutaka Tomida (2 out of 2 patents)

5. Takashi Kawasuji (1 out of 17 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Shionogi & Co., Ltd.. Retrieved from https://idiyas.com/company/shionog

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…